Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Evaluating CHARGE syndrome in congenital hypogonadotropic hypogonadism patients harboring CHD7 variants.

Xu C, Cassatella D, van der Sloot AM, Quinton R, Hauschild M, De Geyter C, Flück C, Feller K, Bartholdi D, Nemeth A, Halperin I, Pekic Djurdjevic S, Maeder P, Papadakis G, Dwyer AA, Marino L, Favre L, Pignatelli D, Niederländer NJ, Acierno J, Pitteloud N.

Genet Med. 2018 Aug;20(8):872-881. doi: 10.1038/gim.2017.197. Epub 2017 Nov 16.

PMID:
29144511
2.

Generation of rationally-designed nerve growth factor (NGF) variants with receptor specificity.

Carleton LA, Chakravarthy R, van der Sloot AM, Mnich K, Serrano L, Samali A, Gorman AM.

Biochem Biophys Res Commun. 2018 Jan 1;495(1):700-705. doi: 10.1016/j.bbrc.2017.11.003. Epub 2017 Nov 3.

PMID:
29108999
3.

Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity.

O'Leary L, van der Sloot AM, Reis CR, Deegan S, Ryan AE, Dhami SP, Murillo LS, Cool RH, Correa de Sampaio P, Thompson K, Murphy G, Quax WJ, Serrano L, Samali A, Szegezdi E.

Oncogene. 2016 Mar 10;35(10):1261-70. doi: 10.1038/onc.2015.180. Epub 2015 Jun 8.

PMID:
26050621
4.

Engineering of weak helper interactions for high-efficiency FRET probes.

Grünberg R, Burnier JV, Ferrar T, Beltran-Sastre V, Stricher F, van der Sloot AM, Garcia-Olivas R, Mallabiabarrena A, Sanjuan X, Zimmermann T, Serrano L.

Nat Methods. 2013 Oct;10(10):1021-7. doi: 10.1038/nmeth.2625. Epub 2013 Sep 1.

PMID:
23995386
5.

The design and characterization of receptor-selective APRIL variants.

Kimberley FC, van der Sloot AM, Guadagnoli M, Cameron K, Schneider P, Marquart JA, Versloot M, Serrano L, Medema JP.

J Biol Chem. 2012 Oct 26;287(44):37434-46. doi: 10.1074/jbc.M112.406090. Epub 2012 Sep 7.

6.

An improved understanding of TNFL/TNFR interactions using structure-based classifications.

Magis C, van der Sloot AM, Serrano L, Notredame C.

Trends Biochem Sci. 2012 Sep;37(9):353-63. doi: 10.1016/j.tibs.2012.06.002. Epub 2012 Jul 11. Review.

PMID:
22789664
7.

A novel classification system to predict the pathogenic effects of CHD7 missense variants in CHARGE syndrome.

Bergman JE, Janssen N, van der Sloot AM, de Walle HE, Schoots J, Rendtorff ND, Tranebjaerg L, Hoefsloot LH, van Ravenswaaij-Arts CM, Hofstra RM.

Hum Mutat. 2012 Aug;33(8):1251-60. doi: 10.1002/humu.22106. Epub 2012 May 11.

PMID:
22539353
8.

Kinetics in signal transduction pathways involving promiscuous oligomerizing receptors can be determined by receptor specificity: apoptosis induction by TRAIL.

Szegezdi E, van der Sloot AM, Mahalingam D, O'Leary L, Cool RH, Muñoz IG, Montoya G, Quax WJ, de Jong S, Samali A, Serrano L.

Mol Cell Proteomics. 2012 Mar;11(3):M111.013730. doi: 10.1074/mcp.M111.013730. Epub 2012 Jan 2.

9.

Protein design with fragment databases.

Verschueren E, Vanhee P, van der Sloot AM, Serrano L, Rousseau F, Schymkowitz J.

Curr Opin Struct Biol. 2011 Aug;21(4):452-9. doi: 10.1016/j.sbi.2011.05.002. Epub 2011 Jun 16. Review.

PMID:
21684149
10.

Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants.

Reis CR, van der Sloot AM, Natoni A, Szegezdi E, Setroikromo R, Meijer M, Sjollema K, Stricher F, Cool RH, Samali A, Serrano L, Quax WJ.

Cell Death Dis. 2010 Oct 21;1:e83. doi: 10.1038/cddis.2010.61.

11.

Computational design of peptide ligands.

Vanhee P, van der Sloot AM, Verschueren E, Serrano L, Rousseau F, Schymkowitz J.

Trends Biotechnol. 2011 May;29(5):231-9. doi: 10.1016/j.tibtech.2011.01.004. Epub 2011 Feb 12. Review.

PMID:
21316780
12.

Computational design of TNF ligand-based protein therapeutics.

van der Sloot AM, Quax WJ.

Adv Exp Med Biol. 2011;691:521-34. doi: 10.1007/978-1-4419-6612-4_54. Review. No abstract available.

PMID:
21153357
13.

Targeting AML through DR4 with a novel variant of rhTRAIL.

Szegezdi E, Reis CR, van der Sloot AM, Natoni A, O'Reilly A, Reeve J, Cool RH, O'Dwyer M, Knapper S, Serrano L, Quax WJ, Samali A.

J Cell Mol Med. 2011 Oct;15(10):2216-31. doi: 10.1111/j.1582-4934.2010.01211.x.

14.

T-RMSD: a fine-grained, structure-based classification method and its application to the functional characterization of TNF receptors.

Magis C, Stricher F, van der Sloot AM, Serrano L, Notredame C.

J Mol Biol. 2010 Jul 16;400(3):605-17. doi: 10.1016/j.jmb.2010.05.012. Epub 2010 May 13.

PMID:
20471393
15.

Building blocks for protein interaction devices.

Grünberg R, Ferrar TS, van der Sloot AM, Constante M, Serrano L.

Nucleic Acids Res. 2010 May;38(8):2645-62. doi: 10.1093/nar/gkq152. Epub 2010 Mar 9.

16.

Protein design in biological networks: from manipulating the input to modifying the output.

Van der Sloot AM, Kiel C, Serrano L, Stricher F.

Protein Eng Des Sel. 2009 Sep;22(9):537-42. doi: 10.1093/protein/gzp032. Epub 2009 Jul 2. Review.

PMID:
19574296
17.

Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors.

Reis CR, van der Sloot AM, Szegezdi E, Natoni A, Tur V, Cool RH, Samali A, Serrano L, Quax WJ.

Biochemistry. 2009 Mar 17;48(10):2180-91. doi: 10.1021/bi801927x.

PMID:
19236007
18.

Loop grafting of Bacillus subtilis lipase A: inversion of enantioselectivity.

Boersma YL, Pijning T, Bosma MS, van der Sloot AM, Godinho LF, Dröge MJ, Winter RT, van Pouderoyen G, Dijkstra BW, Quax WJ.

Chem Biol. 2008 Aug 25;15(8):782-9. doi: 10.1016/j.chembiol.2008.06.009.

19.

DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design.

Tur V, van der Sloot AM, Reis CR, Szegezdi E, Cool RH, Samali A, Serrano L, Quax WJ.

J Biol Chem. 2008 Jul 18;283(29):20560-8. doi: 10.1074/jbc.M800457200. Epub 2008 May 12.

20.

A novel genetic selection system for improved enantioselectivity of Bacillus subtilis lipase A.

Boersma YL, Dröge MJ, van der Sloot AM, Pijning T, Cool RH, Dijkstra BW, Quax WJ.

Chembiochem. 2008 May 5;9(7):1110-5. doi: 10.1002/cbic.200700754.

PMID:
18383241
21.

RGD-avidin-biotin pretargeting to alpha v beta 3 integrin enhances the proapoptotic activity of TNF alpha related apoptosis inducing ligand (TRAIL).

Tarrus M, van der Sloot AM, Temming K, Lacombe M, Opdam F, Quax WJ, Molema G, Poelstra K, Kok RJ.

Apoptosis. 2008 Feb;13(2):225-35.

22.

Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor.

van der Sloot AM, Tur V, Szegezdi E, Mullally MM, Cool RH, Samali A, Serrano L, Quax WJ.

Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8634-9. Epub 2006 May 26.

23.

RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.

Plaza Menacho I, Koster R, van der Sloot AM, Quax WJ, Osinga J, van der Sluis T, Hollema H, Burzynski GM, Gimm O, Buys CH, Eggen BJ, Hofstra RM.

Cancer Res. 2005 Mar 1;65(5):1729-37.

24.

Stabilization of TRAIL, an all-beta-sheet multimeric protein, using computational redesign.

van der Sloot AM, Mullally MM, Fernandez-Ballester G, Serrano L, Quax WJ.

Protein Eng Des Sel. 2004 Sep;17(9):673-80. Epub 2004 Oct 14.

PMID:
15486023
25.

Mutational analysis of a key residue in the substrate specificity of a cephalosporin acylase.

Otten LG, Sio CF, van der Sloot AM, Cool RH, Quax WJ.

Chembiochem. 2004 Jun 7;5(6):820-5.

PMID:
15174165
26.

Binding of phage displayed Bacillus subtilis lipase A to a phosphonate suicide inhibitor.

Dröge MJ, Rüggeberg CJ, van der Sloot AM, Schimmel J, Dijkstra DS, Verhaert RM, Reetz MT, Quax WJ.

J Biotechnol. 2003 Feb 27;101(1):19-28.

PMID:
12523966

Supplemental Content

Loading ...
Support Center